William B Brinkman1, John O Simon2, Jeffery N Epstein2. 1. Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Electronic address: bill.brinkman@cchmc.org. 2. Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Abstract
OBJECTIVE: To describe the prevalence of reasons why children and adolescents stop and restart attention-deficit/hyperactivity disorder (ADHD) medicine and whether functional impairment is present after stopping medicine. METHODS: We used the prospective longitudinal cohort from the Multimodal Treatment of Study of Children With ADHD. At the 12-year follow-up, when participants were a mean of 21.1 years old, 372 participants (76% male, 64% white) reported ever taking ADHD medicine. Participants reported the age when they last stopped and/or restarted ADHD medicine and also endorsed reasons for stopping and restarting. RESULTS: Seventy-seven percent (286 of 372) reported stopping medicine for a month or longer at some time during childhood or adolescence. Participants were a mean of 13.3 years old when they last stopped medicine. The most commonly endorsed reasons for stopping medication related to 1) medicine not needed/helping, 2) adverse effects, 3) logistical barriers of getting or taking medication, and 4) social concerns or stigma. Seventeen percent (64 of 372) reported restarting medicine after stopping for a month or longer. Commonly endorsed reasons for restarting related to medicine being needed or medicine helping; and resolution of logistical barriers to getting or taking medicine. For both stopping and restarting, the proportion endorsing some reasons differed by age range, with the overall pattern suggesting that parental involvement in decisions decreased with age. Nearly all participants had impairment at the assessment after stopping, regardless of whether medication was resumed. CONCLUSIONS: Different reasons for stopping and/or restarting medicine are relevant at different times for different teens. Tailored strategies may help engage adolescents as full partners in their treatment plan.
OBJECTIVE: To describe the prevalence of reasons why children and adolescents stop and restart attention-deficit/hyperactivity disorder (ADHD) medicine and whether functional impairment is present after stopping medicine. METHODS: We used the prospective longitudinal cohort from the Multimodal Treatment of Study of Children With ADHD. At the 12-year follow-up, when participants were a mean of 21.1 years old, 372 participants (76% male, 64% white) reported ever taking ADHD medicine. Participants reported the age when they last stopped and/or restarted ADHD medicine and also endorsed reasons for stopping and restarting. RESULTS: Seventy-seven percent (286 of 372) reported stopping medicine for a month or longer at some time during childhood or adolescence. Participants were a mean of 13.3 years old when they last stopped medicine. The most commonly endorsed reasons for stopping medication related to 1) medicine not needed/helping, 2) adverse effects, 3) logistical barriers of getting or taking medication, and 4) social concerns or stigma. Seventeen percent (64 of 372) reported restarting medicine after stopping for a month or longer. Commonly endorsed reasons for restarting related to medicine being needed or medicine helping; and resolution of logistical barriers to getting or taking medicine. For both stopping and restarting, the proportion endorsing some reasons differed by age range, with the overall pattern suggesting that parental involvement in decisions decreased with age. Nearly all participants had impairment at the assessment after stopping, regardless of whether medication was resumed. CONCLUSIONS: Different reasons for stopping and/or restarting medicine are relevant at different times for different teens. Tailored strategies may help engage adolescents as full partners in their treatment plan.
Authors: Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser Journal: Pediatrics Date: 2011-10-16 Impact factor: 7.124
Authors: Avani C Modi; Ahna L Pai; Kevin A Hommel; Korey K Hood; Sandra Cortina; Marisa E Hilliard; Shanna M Guilfoyle; Wendy N Gray; Dennis Drotar Journal: Pediatrics Date: 2012-01-04 Impact factor: 7.124
Authors: William B Brinkman; Rebecca Baum; Kelly J Kelleher; James Peugh; William Gardner; Phil Lichtenstein; Joshua Langberg; Jeffery N Epstein Journal: J Am Acad Child Adolesc Psychiatry Date: 2016-02-05 Impact factor: 8.829
Authors: S W Evans; W E Pelham; B H Smith; O Bukstein; E M Gnagy; A R Greiner; L Altenderfer; C Baron-Myak Journal: Exp Clin Psychopharmacol Date: 2001-05 Impact factor: 3.157
Authors: James J McGough; Alexandra Sturm; Jennifer Cowen; Kelly Tung; Giulia C Salgari; Andrew F Leuchter; Ian A Cook; Catherine A Sugar; Sandra K Loo Journal: J Am Acad Child Adolesc Psychiatry Date: 2019-01-28 Impact factor: 8.829
Authors: Tanya E Froehlich; William B Brinkman; James L Peugh; Alexandra N Piedra; Daniel J Vitucci; Jeffery N Epstein Journal: J Child Adolesc Psychopharmacol Date: 2019-12-16 Impact factor: 2.576
Authors: Laura C Hart; Scott D Grosse; Melissa L Danielson; Rebecca A Baum; Alex R Kemper Journal: J Atten Disord Date: 2020-09-18 Impact factor: 3.256
Authors: Margaret H Sibley; Mercedes Ortiz; Alexandria Rios-Davis; Courtney A Zulauf-McCurdy; Paulo A Graziano; Leonard Bickman Journal: Adm Policy Ment Health Date: 2021-05-14
Authors: Margaret H Sibley; Paulo A Graziano; Stefany Coxe; Leonard Bickman; Pablo Martin Journal: J Am Acad Child Adolesc Psychiatry Date: 2020-08-28 Impact factor: 13.113